The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

A method of processing whole fresh shellfish, including whole live bivalves, and the resulting compositions in liquid and dried form having a high yield of bioactive components with improved bioavailability. The method includes an enzyme treatment step of applying an enzyme formulation having one or more enzymes to the shellfish, and leaving the shellfish in contact with the enzyme formulation until the flesh and other biological material is substantially separated from the shells or exoskeletons of the shellfish, and liquefying the flesh and biological material using of the same enzyme formulation in the same enzyme treatment step, and/or by applying a different enzyme formulation in the same or one or more subsequent enzyme treatment steps. In a preferred method the shellfish starting material is live at the application of the enzyme. The method does not use mechanical processes to reduce the size of the shellfish before application of the enzyme.

Disclosed are methods of RNA-triggered protein cleavage by the CRISPR Cas7-11-Csx29 complex. A guide RNA specifically hybridizes to a RNA target, and Csx29 cleaves Csx30 when Cas7-11:Csx29 complex binds to the target RNA.

A high-resolution crystallographic structure of the mutant human G267S calpain-5 protease core domain at 2.22 ? resolution is provided. The G267S mutation is associated with hyperactivity of calpain-5 and is linked to the inherited disease, neovascular inflammatory vitreoretinopathy. Methods of using the crystallographic structure in rational design of small molecule drugs that inhibit calpain-5 for treatment of retinal diseases and other diseases associated with calpain-5 hyperactivity are also provided.

Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.